IMARA Inc. (IMRA)
| Market Cap | 140.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.40M |
| Shares Out | 17.85M |
| EPS (ttm) | -2.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $5.48 |
| Previous Close | $5.38 |
| Change ($) | 0.10 |
| Change (%) | 1.86% |
| Day's Open | 5.57 |
| Day's Range | 5.38 - 5.71 |
| Day's Volume | 220,154 |
| 52-Week Range | 5.20 - 36.00 |
Imara Inc (NASDAQ: IMRA) has priced its previously announced underwritten public offering of shares at $6.00 per share for gross proceeds of $50 million. The offering will close by July 16.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pa...
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pa...
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as ...
Imara has continued and expanded the program to award 30 grants totaling $150,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Im...
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687
Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor performa...
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering ...
Company will award grants totaling up to $150,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families Company will award grants totalin...
Atlanta, Georgia--(Newsfile Corp. - March 22, 2021) - Holzer & Holzer, LLC is investigating whether IMARA Inc. ("IMARA" or the "Company") (NASDAQ: IMRA) complied with federal securities laws. On March 5...
Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised ...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to contact R...
NEW YORK, March 10, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to contact Rob...
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutical...
Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap f...
Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs Brings 25 years of experience in the p...
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript
Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
Forte is the first clinical trial of IMR-687 in patients with beta-thalassemia and follows the initiation of Ardent Phase 2b clinical trial of IMR-687 in sickle cell disease Forte is the first clinical ...
Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global Healthcare Conference Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global Healthcare C...
BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call Transcript
Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial
Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease Highly selective, potent, small molecule inhibitor...
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...
Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.
Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Company expands program...
BOSTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients ...
Imara Inc. IMRA, +12.66% announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment.
Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of monothe...
About IMRA
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Industry Biotechnology | IPO Date Mar 12, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol IMRA |
Analyst Forecasts
According to 3 analysts, the average rating for IMARA Inc. stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 538.69% from the latest price.